Does AMIVANTAMAB Cause Agranulocytosis? 7 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Agranulocytosis have been filed in association with AMIVANTAMAB (Rybrevant). This represents 0.9% of all adverse event reports for AMIVANTAMAB.
7
Reports of Agranulocytosis with AMIVANTAMAB
0.9%
of all AMIVANTAMAB reports
3
Deaths
3
Hospitalizations
How Dangerous Is Agranulocytosis From AMIVANTAMAB?
Of the 7 reports, 3 (42.9%) resulted in death, 3 (42.9%) required hospitalization, and 1 (14.3%) were considered life-threatening.
Is Agranulocytosis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for AMIVANTAMAB. However, 7 reports have been filed with the FAERS database.
What Other Side Effects Does AMIVANTAMAB Cause?
Infusion related reaction (62)
Rash (61)
Pulmonary embolism (41)
Dermatitis acneiform (34)
Thrombocytopenia (33)
Paronychia (29)
Diarrhoea (25)
Pneumonitis (24)
Dyspnoea (23)
Nausea (23)
What Other Drugs Cause Agranulocytosis?
CLOZAPINE (1,766)
CYCLOPHOSPHAMIDE (1,242)
RITUXIMAB (1,154)
SULFAMETHOXAZOLE\TRIMETHOPRIM (797)
PANTOPRAZOLE (599)
METHOTREXATE (550)
SODIUM (549)
EPIRUBICIN (491)
METAMIZOLE (438)
DOCETAXEL (436)
Which AMIVANTAMAB Alternatives Have Lower Agranulocytosis Risk?
AMIVANTAMAB vs AMIVANTAMAB-VMJW
AMIVANTAMAB vs AMLODIPINE
AMIVANTAMAB vs AMLODIPINE BESILATE
AMIVANTAMAB vs AMLODIPINE\ATORVASTATIN
AMIVANTAMAB vs AMLODIPINE\BENAZEPRIL